Galderma Group AG (SWX:GALD)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Neuromodulators Revenue	1.37B	1.29B	1.16B
Neuromodulators Revenue Growth	6.62%	10.60%	15.92%
Fillers & Biostimulators Revenue	1.03B	1.01B	966.00M
Fillers & Biostimulators Revenue Growth	1.68%	4.97%	-2.43%
Injectable Aesthetics Revenue	2.40B	2.30B	2.13B
Injectable Aesthetics Revenue Growth	4.39%	8.04%	6.80%
Dermatological Skincare Revenue	1.38B	1.33B	1.21B
Dermatological Skincare Revenue Growth	3.31%	9.82%	11.35%
Therapeutic Dermatology Revenue	881.00M	780.00M	741.70M
Therapeutic Dermatology Revenue Growth	12.95%	5.16%	9.17%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
USA Revenue	1.92B	1.81B	1.81B
USA Revenue Growth	6.30%	-0.03%	4.20%
International Revenue	2.73B	2.60B	2.27B
International Revenue Growth	5.08%	14.48%	12.28%

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Neuromodulators Constant Currency Growth	11.80%	-
Fillers & Biostimulators Constant Currency Growth	7.00%	-
Injectable Aesthetics Constant Currency Growth	9.60%	-
Dermatological Skincare Constant Currency Growth	10.70%	-
Therapeutic Dermatology Constant Currency Growth	6.10%	-
Total Constant Currency Growth	9.30%	-

Updated Jun 30, 2025. Data Source: Fiscal.ai.